respiratory tract infection

Translate Bio Inc (NASDAQ: TBIO) has presented positive results from a preclinical study of its mRNA-based therapeutic designed to treat the pulmonary component of primary ciliary dyskinesia (PCD). Mutations in the genes that cause PCD result in ineffective mucociliary clearance,...

Clinical stage biopharma company resTORbio, Inc. (NASDAQ: TORC)'s TORC1 inhibition program uses a protein called serine/threonine kinase that aims to regulate aging and aging-related diseases conditions without undesirable side effects. The Analyst Wedbush analyst Robert Driscoll...